Member Info for OAPK20

“For set 1 mean CIZ1b level in individuals without diagnosed tumours established a threshold that correctly classified 98% of small cell lung cancers (SCLC) and non SCLC patients (receiver operator characteristic AUC 0.958)

Within set 2, comparison of stage 1 non-SCLC with asymptomatic age matched smokers, or individuals with benign lung nodules, correctly classified 95% of patients (AUCs 0.913, 0.905) with overall specificity of 76% and 71% respectively. Moreover using the mean of controls in set 1, we achieved 95% sensitivity among stage 1 non SCLC patients in set 2 with 74% specificity, demonstrating the robustness of the classification. Thus CIZ1b performs with clinically useful accuracy and could potentially satisfy the unmet need for a circulating biomarker for early detection of lung cancer.”

Rob please post the link to 98% accuracy

0.5 of a difference in price?

Dazah what’s your chart set up for Golden cross ?

Beast - it’s 36% dilution (not including the separate conditional retail offer ) and not to mention ;

“ The Company recognises the risks associated with the launch of a new test (including the time to obtain the initial Local Coverage Determination) and taking into account the potential timing effects of this for the build-up of Tutivia(TM) sales in 2024, is reducing its expectations for Tutivia(TM) revenue for 2024. The effect of this reduction is expected to be at least partially offset by revenue from other sources including research collaborations. “

The Placing will be conducted at a price of 9.0 pence per Ordinary Share (the "Issue Price"). The Issue Price represents a discount of 11.1 per cent. to Verici's closing mid-price on 23 January 2024 (being the last practicable day prior to the publication of this Announcement).

The Placing will involve the issue of not less than 61,111,111 new Ordinary Shares (the "Placing Shares"), representing at least 35.9 per cent. of the existing issued ordinary share capital of the Company.

In addition to the Placing, it is proposed that there will be a separate conditional retail offer to existing Shareholders via the BookBuild Platform (the "Retail Offer" and, together with the Placing, the "Fundraising") to raise further proceeds for the Company at the Issue Price via the issue of further new Ordinary Shares (the "Retail Offer Shares", together with the Placing Shares, the "New Ordinary Shares"). The Retail Offer aims to provide existing retail Shareholders in the Company with an opportunity to participate in the Fundraising.

Exactly.

Are you a shareholder in those organisations?

That’s the point Tech. Acting like a junior or mining company tweeting fluff and pump.

September was the last update. AL says he won’t RNS pointless updates, he needs to have a word about pointless Tweets. Why they doing it ?

More fluff no substance

Approx 400-500 (including living donor transplants) per week. So with around 100 per week using both Tutivia(TM) (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava(TM) (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection

Then $265000 per week or $13,780,000 per annum. ?

Is that about right?

Nearly 1 year on. Think of the lives that could be saved with the CIZ1b test detecting Stage 1 lung cancer and the cost savings to the NHS on unnecessary scans.

CIZ need to move

Targeted lung cancer screening to help detect cancer sooner and speed up diagnosis

People aged 55 to 74 with a GP record including a history of smoking will be assessed and invited for screenings and smoking cessation services

Rollout follows the success of the first phase of the targeted lung health check scheme by NHS England with 76% of lung cancers in those tested caught at an earlier stage

A national targeted lung cancer screening programme designed to catch cancer sooner or prevent it altogether has been announced by the Prime Minister and Secretary of State for Health and Social Care.

Each year the programme - which will cost £270 million annually once fully implemented - is expected to detect cancer in as many as 9,000 people, deliver almost one million scans and provide treatment earlier.

The rollout follows a successful opening phase where approximately 70% of the screening took place in mobile units parked in convenient places - such as supermarket car parks - to ensure easy access and focused on more deprived areas where people are 4 times more likely to smoke.

The programme, backed by a recommendation from the UK National Screening Committee - will use patient’s GP records for those aged 55 to 74 to identify current or former smokers. Patients will have their risk of cancer assessed based on their smoking history and other factors and those considered high risk will be invited for specialist scans every 2 years.

It hit £5 ish the the notorious “it’s a duster” crash day before news

Remember RKH and it’s a “duster”

Cheers Neil saw your post after I asked. Might be a stupid question to others but I wasn’t sure.

Nice to see the spread closing up but there’s always one

110,970 @2.55.

:-)

Are OBD doing a placing ?

Also their test is a companion test not a standalone test. PSA tests are being criticised for their accuracy so raises a question as to whether medical bodies would pay for 2 tests to get a result when potentially 1 test could do the job.

EpiSwitch Prostate Screening (PSE) is designed to run alongside a standard PSA test

PSE boosts PSA predictive accuracy from 55% to 94%1 for determining the presence or absence of prostate cancer

PSE is immediately available to men in the US using a centralized high-complexity CLIA-certified lab facility in Frederick, Maryland,

Increased accuracy of diagnosis should significantly reduce false positives and in turn unnecessary referrals for more invasive procedures with longer term health risks

Just a thought but would CIZ seek CAP accreditation separately for the CIZ1b lung test or would that come from CorePath anyway (CAP accreditation lab) on commercial launch ?

2.4-2.7 is a joke. If they can’t shift what they have they need to drop the ask. Been pegging this back too long

£175M - 48p a share

The question was

“What price would you be happy for Buyout ?“

I would be happy with £10

Sorry. £100